Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants - Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants - Reviva Pharmaceuticals (NASDAQ:RVPH)

CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of an underwritten public offering of 12,000,000 shares of common stock together with series A war…

Reviva Announces Proposed Public Offering

December 16, 2024 17:18 ET  | Source: Reviva Pharmaceuticals CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today ann…

CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D

Reviva Pharmaceuticals announces an $18M public offering to fund R&D, with positive data from Phase 3 brilaroxazine trial.

Reviva Pharmaceuticals Announces $18M Public Offering with Warrant Package to Fund R&D Pipeline

Reviva Pharmaceuticals secures fresh capital through a strategic offering of 12M shares and warrants, earmarking funds for research advancement and operational growth.